Not a Medical Tool: Deepinder Goyal Defends Temple AI Device
Zomato founder Deepinder Goyal clarifies that his new Temple device is for fitness and AI, not medical diagnosis, amid pricing controversy.
Deepinder Goyal, the founder of Zomato and the visionary behind the new Deepinder Goyal Temple device, has stepped forward to address the growing storm of criticism surrounding his latest venture. Amidst questions regarding its high price tag and the scientific validity of its claims, Goyal has clarified that Temple is strictly a fitness and artificial intelligence (AI) tool, not a medical instrument designed to diagnose or prevent diseases.
No Medical Claims, No Doctor Replacement
Taking to social media to set the record straight, Goyal emphasized that the company has never positioned Temple as a healthcare device. He was firm in stating that the product does not serve as a substitute for professional medical advice.
"Temple is strictly a fitness + AI device, and we've made no medical claims. Temple is not proven to diagnose or prevent any disease. It doesn't do anything which replaces the need for you to see a doctor," Goyal stated.
Addressing the Pricing Controversy
A significant portion of the backlash has centered on the device's cost. Goyal responded to these concerns by highlighting the immense effort and resources invested in the product's development. He maintained that the pricing reflects the value the company attributes to the innovation.
While offering a polite apology to those upset by the cost, he suggested that skeptics wait for real-world feedback. He noted that users are free to wait for peer-reviewed proof or user reviews before deciding if the device is worth their investment, adding, "Nobody is forcing you to buy."
A Global Product, Not Just for India
In a surprising revelation, Goyal clarified that Temple was not primarily designed for the Indian market. He revealed that the product is aimed at a global audience, with very low expectations for domestic sales.
According to Goyal, the company expects that no more than 1 per cent of the total Temple devices sold will be in India. He urged critics to check the pricing through a global lens, reiterating that "Temple is not made for India. It's made for the world."
The Tech Behind Temple: Entropy and Brain Flow
Goyal also took the opportunity to dive into the technical aspects of the device to clear up misconceptions:
- Entropy: Goyal revealed that Entropy is the primary focus of Temple. While the company has not yet published data on this, he confirmed that plans to do so are in place.
- Brain Flow: While studies on Brain Flow were released first, Goyal clarified that it is not the main feature. He promised to publish a detailed note explaining how Brain Flow is calculated, its specific uses, and its limitations.
- Roomdeaf AI: This was described as an expansion of the device's capabilities and a part of the broader vision for Temple, rather than a pivot in direction.
Competing on a Global Stage
Closing his defense, Goyal expressed his desire for the company to compete on merit globally. He stated that he is not seeking support simply because the venture is an Indian startup. Instead, he believes the product should be supported by those who value early innovation and its potential to enhance human lives.